# Ascletis Pharmaceuticals Co., Ltd. trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Ascletis Pharmaceuticals Co., Ltd. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Ascletis Pharmaceuticals Co., Ltd.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/ascletis-pharmaceuticals-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 8, 2024 | NCT06248008 | A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Acne | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06248008) |
| January 5, 2024 | NCT06192264 | A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne... | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Acne | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06192264) |
| February 8, 2023 | NCT05718518 | Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy, COVID-19 | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05718518) |
| October 27, 2022 | NCT05596045 | Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Withdrawn | SARS CoV 2 Infection | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05596045) |
| August 31, 2022 | NCT05523141 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | SARS CoV 2 Infection | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05523141) |
| April 15, 2022 | NCT05330143 | Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | HIV-1-infection, HIV Infections, PD-L1 Gene Mutation | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05330143) |
| March 18, 2022 | NCT05287399 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Advanced Solid Tumors | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05287399) |
| November 12, 2021 | NCT05118776 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 | Unknown | Recurrent Glioblastoma | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05118776) |
| November 4, 2021 | NCT05107778 | Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Hepatitis B, Chronic | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05107778) |
| November 2, 2021 | NCT05104125 | Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Acne Vulgaris | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05104125) |
| July 16, 2021 | NCT04965337 | Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04965337) |
| April 13, 2021 | NCT04843449 | Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04843449) |
| September 14, 2020 | NCT04547894 | A Study of the Pharmacokinetics of ASC09F in Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04547894) |
| August 26, 2020 | NCT04527250 | A Study of the Relative Bioavailability of ASC41 in Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04527250) |
| July 10, 2020 | NCT04465890 | A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Chronic Hepatitis b | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04465890) |
| April 24, 2020 | NCT04358523 | A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04358523) |
| April 20, 2020 | NCT04352361 | Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04352361) |
| February 13, 2018 | NCT03430830 | A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Chronic Hepatitis c | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03430830) |
| December 5, 2017 | NCT03362814 | Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis... | Ascletis Pharmaceuticals Co., Ltd. | Phase 2/3 | Completed | HCV | 425 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03362814) |
| September 20, 2017 | NCT03288636 | Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | HCV | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03288636) |
| January 13, 2017 | NCT03020134 | Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020134) |
| January 13, 2017 | NCT03020095 | Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Chronic Hepatitis C | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020095) |
| January 13, 2017 | NCT03020082 | Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III | Ascletis Pharmaceuticals Co., Ltd. | Phase 3 | Completed | Chronic Hepatitis C | 141 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020082) |
| January 13, 2017 | NCT03020004 | Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 | Completed | Chronic Hepatitis C | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03020004) |
| January 13, 2017 | NCT03019991 | Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China | Ascletis Pharmaceuticals Co., Ltd. | Phase 1 | Completed | Healthy | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03019991) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 2 | 6 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 23 |
| Unknown | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C, Chronic | 4 |
| Acne Vulgaris | 3 |
| COVID-19 | 3 |
| Hepatitis B, Chronic | 2 |
| HIV Infections | 1 |
| Glioblastoma | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Emergency departments in the United States](https://specstream.ai/data/businesses/emergency-departments/united-states)
- [Prosthetics providers in the United States](https://specstream.ai/data/businesses/prosthetics-providers/united-states)
- [Cardiothoracic surgery practices in the United States](https://specstream.ai/data/businesses/cardiothoracic-surgery-practices/united-states)
- [Merchandising companies in the United States](https://specstream.ai/data/businesses/merchandising-companies/united-states)
- [Appraisers in the United States](https://specstream.ai/data/businesses/appraisers/united-states)
